Indole-3-acetic acid prevents steatosis by modulating lipid metabolism in the liver, primarily by reducing lipogenesis while promoting fat breakdown, achieved through mechanisms involving the activation of the aryl hydrocarbon receptor (AhR), which then downregulates key genes involved in fat synthesis, leading to decreased inflammation and oxidative stress within the liver tissue, thereby mitigating the progression of MASLD. Here, AHR is linked to metabolic dysfunction-associated steatotic liver disease.